Explore The Clinical Performance Insights of Aiosyn Mitosis Breast at USCAP 2024
admin@pathologynews.com2024-03-22T09:26:43+00:00Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney diseases, recently conducted a clinical performance study in collaboration with Radboud university medical center. The study, aimed at evaluating the benefits offered by Aiosyn Mitosis Breast within the pathology practice, will be presented during the 113th USCAP Annual Meeting.










